Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Japan Sales of “Huge Seller” Quartet Each Break 110 Billion Yen in 2015: IMS
Four drugs that will be hit by a new re-pricing rule for fast-growing blockbusters all rang up Japan sales of over 110 billion yen in 2015 on an NHI price basis, according to data released by IMS Health on February…
To read the full story
Related Article
- Gilead, Bristol Take Quantum Leaps in 2015, Lilly Logs Double-Digit Growth: IMS
February 10, 2016
- Sovaldi Best-Selling Drug in July-September after May Launch: IMS
November 11, 2015
- Antithrombotic Agent Sales Up 7.4% in 2014 on Buoyant Plavix, Xarelto: IMS
February 13, 2015
- Japan Pharma Market Grows 1.4% in 2014, Plavix Retains Crown in Sales Ranking: IMS
February 13, 2015
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…